Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Bayer‘s Drive for Sustainable Healthcare Innovations in Asia Prof. Dr. A. Busch Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery Bayer HealthCare [email protected] R&D Focus of Bayer Pharmaceuticals Addresses Healthcare Challenges in Asia-Pacific Oncology/ Gynecology Cell Cycle / Survival Signaling Immunotherapy / AntibodyDrug Conjugates Pulmonary Hypertension / Heart Failure Thrombosis / Acute Coronary Syndrome Tumor Metabolism / Hypoxia Cardiorenal Syndrome (CRS) Chromatin Modulation / OncoGenomics Anemia and other blood diseases Endometriosis LCM long acting factor VIII Uterine Fibroids Highly competitive internal platforms SMOLs (compound library and screening) Antibody-platform (including ADCs) DMPK, Tox, CMC Page 2 Cardiology/ Hematology Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Asian-prevalent Gastric, Liver and Lung Cancers Present a Major Health Problem in the Region Liver Cancer World Regions Stomach Cancer World Regions World Age-standardized incidence rates per 100,000 population Asia alone had the highest number of cancer deaths in the world with over 4 million (54%) and over 6 million new cancer cases in 2008 1 Cancer is the leading cause of death in Singapore, causing 30% of deaths in 2011 2 Original data sources: Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer,2010. Available from: http://globocan.iarc.fr 1 CancerStats:Cancer Worldwide (Sept 2011). WHO International Agency for Research on Cancer. Retrieved from http://publications.cancerresearchuk.org/downloads/Product/CS_CS_WORLD.pdf on 05/12/12 2 Ministry of Health Singapore. www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Principal_Causes_of_Death.html Sorafenib - Fighting Liver Cancer, a Deadly Disease with High Prevalence in Asia Liver cancer is the third leading cause of cancer-related deaths worldwide, fifth most common cancer in men, and especially prevalent in Asia Hepatocellular Carcinoma (HCC) is the most common form of liver cancer Poor prognosis for patients with all histologies (5-year survival rate is only ~ 10% or less for non-resectable tumors) Bayer´s Tyrosine Kinase Inhibitor Sorafenib is The only approved systemic therapy for advanced liver cancer The first oral targeted therapy to treat advanced kidney cancer Comprehensive development program underway in thyroid and breast cancer Page 4 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Bayer´s Continuous Search for Cancer Solutions in Asia * metastatic colorectal cancer and gastrointestinal stromal tumors Page 5 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Sustaining Innovation in Asia-Pacific by Combining Bayer´s Competitive Platforms with a Flexible Partnering Strategy Joint labs Strategic partnerships Consortia Joint research Crowdsourcing Integration Co-location Multiple projects, close interaction Individual project Partner Outsourcing Page 6 Licensing Transition of assets Incubator Arm‘s length Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Examples DKFZ OncoMed Biotech companies Type Academic institutions Within Bayer IMI China, Singapore Grants4Targets Ardea CoLaborator Bayer´s Oncology Partnerships from Bench to Bedside Richie Soong, Patrick Tan Hung Huynh Goh Boon Cher - In vitro analyses of drug candidates - Identification of stratification markers - Mutation analysis in Asian population - Xenograft models for in vivo analysis of cancer drug candidates - Paired biopsy study with Regorafenib to assess biomarkers in Colorectal Ca -Gastric Cancer, HCC -Gastric Cancer, HCC, NSCLC Research Target Lead Lead discovery discovery optimization Kishore Bhakoo - Target discovery (tumor metabolism, HCC), imaging for translational research Pre-clinical development Goh Boon Cher, Hsieh Wen-son Clinical development Phase I Phase II Phase III Goh Boon Cher, Daniel Tan - Clinical studies In vitro and xenograft studies to evaluate potential activity of Bayer drug in Nasopharyngeal Ca Bayer Singapore integrated translational oncology network joins expertise together to develop novel therapies for Asian cancer patients Page 7 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Bayer – Science for a Better Life Bayer addresses the high unmet medical need of increasing burden of disease in the Asia-Pacific region (Asian-prevalent cancers, eye diseases, heart diseases and stroke) by bringing innovative therapies to the patients Bayer is strongly committed to Oncology with several late stage and launched compounds in HCC, RCC, CRC, GIST and CRPC (Sorafenib, Regorafenib and Radium-223) as well as a strong early clinical pipeline Partnerships with regional and local institutions and academia as well as increasing clinical trial activities are key components of Bayer HealthCare’s sustainable R&D strategy in Asia-Pacific Prime example of sustainable R&D efforts: Bayer-Singapore Integrated Translational Oncology Network maximizes value of expertise to address innovation needs for Asian cancer patients Page 8 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Page 9 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 10 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG Healthcare Macro Trends in Asia-Pacific Addressed by Bayer R&D Strategy High unmet medical need in various diseases Asia-specific differences in disease biology (e.g. cancer) Need for sustainable healthcare innovation Growing and aging population Demographic change Page 11 Singapore, WHSRMA, April 2013 Increasing value demand and requirements by patients Prof. A. Busch, Bayer Pharma AG Innovation Efforts in China Bayer-Tsinghua-Center BTC Joint Research Center for innovative drug discovery with University of Tsinghua Culminated budget of US$ 1.000.000 per year (US$ 700 000 for joint projects) Governance Director: Prof. Yigong Shi, Chairman: Prof L. Zhang, Vice Chairman: Prof. E. Ottow Deputy director: Dr. J. Fanghaenel, Members: Prof. Y. Li, Prof. H. Wang, Prof. H. Wild, Dr. U. Nielsch, Dr. J. Hu 22 joint research projects successfully initiated (e.g. in structure biology and peptide chemistry) 42 Bayer Investigator Awards granted to outstanding scientist from Tsinghua University Prof. Dong as first Bayer chair holder nominated at Tsinghua University Promoting scientific exchange: Bayer-Tsinghua Joint Symposium on Drug Discovery (2010, 2011, 2012) Bayer Lectures, Tsinghua Bayer Summer School Multiple visits of Tsinghua PI’s to research sites in Germany and the US Page 12 Singapore, WHSRMA, April 2013 Prof. A. Busch, Bayer Pharma AG